Kati Vandermeulen

1.8k citations

19 papers · 713 indexed · 1 hit paper · h-index 12

Infectious Diseases top 2%
Virology top 1%
Emergency Medicine top 5%
Epidemiology
Pediatrics, Perinatology and Child Health

Co-authors: Brian Wynne Lesley Kahl Martin Gartland Michael Aboud Mark Underwood Elizabeth A. Blair Cynthia Brinson Thomas N. Kakuda
Topics: HIV/AIDS drug development and treatment (19 papers)HIV Research and Treatment (14 papers)HIV/AIDS Research and Interventions (8 papers)
Cited by: Virology Infectious Diseases Emergency Medicine
Journals: The Lancet AIDS Journal of Antimicrobial Chemotherapy
Partner nations: Belgium United States United Kingdom

In The Last Decade

Kati Vandermeulen

19 papers receiving 677 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies

2018 243 citations Josep M. Llibre, Chien‐Ching Hung et al. The Lancet profile →

Peers

Countries citing papers authored by Kati Vandermeulen

Since Specialization

Citations

This map shows the geographic impact of Kati Vandermeulen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kati Vandermeulen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kati Vandermeulen more than expected).

Fields of papers citing papers by Kati Vandermeulen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kati Vandermeulen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kati Vandermeulen. The network helps show where Kati Vandermeulen may publish in the future.

Co-authorship network of co-authors of Kati Vandermeulen

This figure shows the co-authorship network connecting the top 25 collaborators of Kati Vandermeulen. A scholar is included among the top collaborators of Kati Vandermeulen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kati Vandermeulen. Kati Vandermeulen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

#	Work	Indexed citations
1	Long-Term Efficacy, Safety, and Durability of Cabotegravir and Rilpivirine as 2-Drug Oral Maintenance Therapy After 6 Years of Study 2022 ·Open Forum Infectious Diseases ·Kenneth Sutton,Jerome De Vente,Roger LeBlanc,Edwin DeJesus,Graham Smith,Anthony Mills,Jean-Guy Baril,Marty St. Clair,Britt Stancil,Kati Vandermeulen,William Spreen	2
2	Brief Report: Evaluation of Inflammation and Atherogenesis Biomarkers Through 148 Weeks Postswitch to Dolutegravir and Rilpivirine in SWORD-1/SWORD-2 2022 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·Josep M. Llibre,Luís F. López‐Cortés,(unknown),Brian Wynne,Jessica Matthews,Rodica Van Solingen‐Ristea,Kati Vandermeulen,Jean van Wyk,Lesley Kahl	7
3	Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label phase 3 FLAIR study 2021 ·The Lancet HIV ·Chloe Orkin,Enrique Bernal,Darrell H. S. Tan,Harold Katner,Hans‐Jürgen Stellbrink,Elena Belonosova,(unknown),Sandy Griffith,Shanker Thiagarajah,Rodica Van Solingen‐Ristea,Susan L. Ford,Herta Crauwels,Parul Patel,Amy Cutrell,Kimberly Y. Smith,Kati Vandermeulen,(unknown),Marty St. Clair,William Spreen,Ronald D’Amico	88
4	Long-acting cabotegravir and rilpivirine for HIV-1 suppression: switch to 2-monthly dosing after 5 years of daily oral therapy 2021 ·AIDS ·Anthony Mills,Gary Richmond,Cheryl Newman,Olayemi Osiyemi,Jerry Cade,Cynthia Brinson,Jerome De Vente,David A. Margolis,Kenneth Sutton,(unknown),(unknown),Jeremy Roberts,Cynthia McCoig,Cindy Garris,Kati Vandermeulen,William Spreen	25
5	1029. Long-Term Patient Adherence and Management of Treatment Interruptions With Long-Acting Injectable Cabotegravir + Rilpivirine for Maintenance Therapy in Phase IIb/III Studies 2020 ·Open Forum Infectious Diseases ·(unknown),Sterling Wu,Feifan Zhang,David Dorey,Ronald D’Amico,Sandy Griffith,Kenneth Sutton,Cynthia McCoig,(unknown),Joseph W. Polli,David M. Margolis,Rodica Van Solingen‐Ristea,Kati Vandermeulen,William Spreen,Parul Patel	2
6	116. Antiviral Activity and Safety of Long-acting Cabotegravir (CAB LA) Plus Long-acting Rilpivirine (RPV LA), Administered Every 2 Months (Q2M), in Hiv-positive Subjects: Results from the POLAR Study 2020 ·Open Forum Infectious Diseases ·Anthony Mills,Gary Richmond,Cheryl Newman,Olayemi Osiyemi,Jerry Cade,Cynthia Brinson,Jerome De Vente,Nisha Andany,David M. Margolis,Kenneth Sutton,(unknown),Jeremy Roberts,Cynthia McCoig,Kati Vandermeulen,William Spreen	1
7	638. Safety, Efficacy, and Durability of Long-Acting CAB and RPV as Maintenance Therapy for HIV-1 Infection: LATTE-2 Week 256 Results 2020 ·Open Forum Infectious Diseases ·Graham Smith,Keith Henry,Daniel Podzamczer,Mar Masiá,Christopher Bettacchi,Keikawus Arastéh,Hans Jaeger,Marie-Aude Khuong-Josses,Kenneth Sutton,Feifan Zhang,Cynthia McCoig,Kati Vandermeulen,Rodica Van Solingen‐Ristea,William Spreen,David M. Margolis	2
8	Brief Report: Durable Suppression and Low Rate of Virologic Failure 3 Years After Switch to Dolutegravir + Rilpivirine 2-Drug Regimen: 148-Week Results From the SWORD-1 and SWORD-2 Randomized Clinical Trials 2020 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·Jean van Wyk,Chloe Orkin,Rafael Rubio,Johannes R. Bogner,David Baker,Marie-Aude Khuong-Josses,(unknown),Konstantinos Angelis,Lesley Kahl,Jessica Matthews,Ruolan Wang,Mark Underwood,Brian Wynne,(unknown),Kati Vandermeulen,Martin Gartland,Kimberly Y. Smith	32
9	Efficacy and safety of dolutegravir–rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, open-label, phase 3 SWORD-1 and SWORD-2 studies 2019 ·The Lancet HIV ·Michael Aboud,Chloe Orkin,Daniel Podzamczer,Johannes R. Bogner,David Baker,Marie-Aude Khuong-Josses,(unknown),Konstantinos Angelis,Lesley Kahl,Elizabeth A. Blair,Kimberly K. Adkison,Mark Underwood,Jessica Matthews,Brian Wynne,Kati Vandermeulen,Martin Gartland,Kimberly Y. Smith	77
10	Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studiesbreakdown → 2018 ·The Lancet ·Josep M. Llibre,Chien‐Ching Hung,Cynthia Brinson,Francesco Castelli,Pierre‐Marie Girard,Lesley Kahl,Elizabeth A. Blair,(unknown),Brian Wynne,Kati Vandermeulen,Mark Underwood,(unknown),Martin Gartland,Michael Aboud	243
11	Switch from tenofovir disoproxil fumarate combination to dolutegravir with rilpivirine improves parameters of bone health 2017 ·AIDS ·Grace A. McComsey,Sergio Lupo,(unknown),(unknown),(unknown),Lesley Kahl,(unknown),Brian Wynne,Kati Vandermeulen,Martin Gartland,(unknown),Michael Aboud	43
12	Sword 1 and 2: Subgroup Analysis of 48 Week Results by Age, Race and Gender 2017 ·Open Forum Infectious Diseases ·Sharon Walmsley,Gary Richmond,Fritz Bredeek,Moti Ramgopal,Chien‐Ching Hung,Elizabeth A. Blair,Lesley Kahl,Mark D. Underwood,(unknown),Kati Vandermeulen,Brian Wynne,Michael Aboud	1
13	Pharmacokinetic evaluation of the interaction between etravirine and rifabutin or clarithromycin in HIV-negative, healthy volunteers: results from two Phase 1 studies 2013 ·Journal of Antimicrobial Chemotherapy ·Thomas N. Kakuda,Brian Woodfall,Tine De Marez,Marc Peeters,Kati Vandermeulen,(unknown),Richard M. W. Hoetelmans	11
14	Assessment of the steady‐state pharmacokinetic interaction between etravirine administered as two different formulations and tenofovir disoproxil fumarate in healthy volunteers 2009 ·HIV Medicine ·Thomas N. Kakuda,Monika Schöller‐Gyüre,Goedele De Smedt,Geerard L. Beets,(unknown),(unknown),Kati Vandermeulen,(unknown),(unknown)	27
15	Effect of steady-state etravirine on the pharmacokinetics and pharmacodynamics of ethinylestradiol and norethindrone 2009 ·Contraception ·Monika Schöller‐Gyüre,Thomas N. Kakuda,Brian Woodfall,(unknown),Monika Peeters,Kati Vandermeulen,Richard M. W. Hoetelmans	29
16	Pharmacokinetic and Pharmacodynamic Study of the Concomitant Administration of Methadone and TMC125 in HIV‐Negative Volunteers 2008 ·The Journal of Clinical Pharmacology ·Monika Schöller‐Gyüre,Wim van den Brink,Thomas N. Kakuda,Brian Woodfall,(unknown),(unknown),(unknown),Monika Peeters,Kati Vandermeulen,Richard M. W. Hoetelmans	33
17	Effects of Different Meal Compositions and Fasted State on the Oral Bioavailability of Etravirine 2008 ·Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy ·Monika Schöller‐Gyüre,Marta Boffito,Anton Pozniak,(unknown),Thomas N. Kakuda,Brian Woodfall,Veerle Vyncke,Monika Peeters,Kati Vandermeulen,Richard M. W. Hoetelmans	35
18	Single- and multiple-dose pharmacokinetics of etravirine administered as two different formulations in HIV-1-infected patients 2008 ·Antiviral Therapy ·Thomas N. Kakuda,(unknown),Cassy Workman,Keikawus Arastéh,Anton Pozniak,Goedele De Smedt,Greet Beets,Monika Peeters,Kati Vandermeulen,Brian Woodfall,Richard M. W. Hoetelmans	27
19	An open randomized controlled trial of zidovudine plus lamivudine versus stavudine plus lamivudine 1998 ·AIDS ·Norbert A. Foudraine,J J de Jong,Gerrit Jan Weverling,Birgit van Benthem,Jaap Maas,Ireneus P.M. Keet,Suzanne Jurriaans,Marijke Roos,Kati Vandermeulen,Frank de Wolf,Joep M. A. Lange	28

About Kati Vandermeulen

Kati Vandermeulen is a scholar working on Virology, Infectious Diseases and Hepatology, having authored 19 papers that have together received 713 indexed citations. Recurring topics across this work include HIV/AIDS drug development and treatment (19 papers), HIV Research and Treatment (14 papers) and HIV/AIDS Research and Interventions (8 papers). The work is most often cited by research in Virology (480 citations), Infectious Diseases (651 citations) and Emergency Medicine (177 citations). Kati Vandermeulen has collaborated with scholars based in Belgium, United States and United Kingdom. Frequent co-authors include Brian Wynne, Lesley Kahl, Martin Gartland, Michael Aboud, Mark Underwood, Elizabeth A. Blair, Cynthia Brinson, Thomas N. Kakuda, Josep M. Llibre and Chien‐Ching Hung. Their work appears in journals such as The Lancet, AIDS and Journal of Antimicrobial Chemotherapy.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact